December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

17.40 -7.47 (-30.04%)
Streaming Delayed Price Updated: 12:19 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
From uniQure Inc.
Via GlobeNewswire
News headline image
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode ↗
The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 
Via Stocktwits
News headline image
Earnings Outlook For uniQure ↗
 
Via Benzinga
News headline image
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 9, 2025 ↗
 
Via Benzinga
News headline image
uniQure to Announce First Quarter 2025 Financial Results
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ 
From uniQure Inc.
Via GlobeNewswire
News headline image
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Which stocks are moving on Thursday? ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic ↗
The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130. 
Via Stocktwits
Topics Bankruptcy
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? ↗
uniQure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan Drug statuses. 
Via Benzinga
News headline image
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years ↗
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four. 
Via Benzinga
News headline image
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Pricing of its Public Offering
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
News headline image
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? ↗
Via The Motley Fool
News headline image
S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings ↗
 
Via Benzinga
News headline image
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Dow Falls 150 Points; Oracle Posts Downbeat Results ↗
 
Via Benzinga
Topics Stocks
News headline image
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.